Diastone

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Diastone

Quick Facts: Diastone

Property Description
Active Ingredient Diclofenac (Sodium or Potassium salt)
Pharmacological Class Nonsteroidal Anti-inflammatory Drug (NSAID)
Chemical Class Phenylacetic acid derivative
Common Forms Tablets, Capsules, Injection Solutions, Gels
Origin/Type Synthetic Compound

Diastone: Classification, Composition, and Origin

Diastone is a medicinal product whose active component is Diclofenac, classifying it as a Nonsteroidal Anti-inflammatory Drug (NSAID). This medication is a synthetic compound that belongs specifically to the Phenylacetic acid derivative chemical class.

The product's identity is defined by its core active substance, Diclofenac, which is typically formulated as Diclofenac Sodium or Diclofenac Potassium. Diclofenac functions to decrease substances in the body that cause pain and inflammation. This anti-inflammatory and analgesic function is clinically recognized for effective symptomatic relief across various patient presentations. While the standard preparation is a single-active ingredient formulation, some specialized variants, such as Diastone Flex, are combination products that integrate an additional active component, typically the muscle relaxant Pridinol Mesylate, to target symptoms involving both inflammation and muscle spasm.


Diastone: Available Forms and General Therapeutic Purpose

Diastone is available in several essential dosage forms and intended for multiple routes of administration, allowing for targeted or systemic symptom management. Common forms include oral solid preparations, solutions intended for injection (parenteral route), and topical preparations like gels and patches. This versatility in form provides differentiated options for managing pain, such as the use of topical gels for localized relief of muscular aches, contrasting with systemic use for generalized joint stiffness.

The medication's general purpose is to provide comprehensive relief by addressing conditions characterized by concurrent pain and inflammation. Its fundamental therapeutic mission is to mitigate the physical discomfort, swelling, and stiffness associated with the body’s inflammatory response. Diclofenac is characterized by its function as an anti-inflammatory and analgesic agent. By reducing the generation of key inflammatory chemical mediators, Diastone helps stabilize the body's reaction to injury or disease, thereby improving overall comfort and mobility.

What side effects are possible with Diastone?

Possible Side Effects and Safety Information

The safety profile of Diastone (Diclofenac), as classified in official regulatory documents, is structured around adverse reactions categorized by frequency and the body system affected. As a Nonsteroidal Anti-inflammatory Drug (NSAID), its use carries documented risks related primarily to the gastrointestinal and cardiovascular systems.

Official Adverse Reaction Categories

Classification Examples of Officially Listed Effects
Common Nausea, vomiting, diarrhea, dyspepsia, abdominal pain, headache, dizziness, and elevation of liver enzymes (transaminases).
Rare Severe hepatic reactions (e.g., liver failure), serious allergic reactions (anaphylaxis), and severe cutaneous adverse reactions (SCARs).

Regulatory Safety Warnings

Official labeling emphasizes the potential for Serious Adverse Reactions, including fatal cardiovascular thrombotic events (such as myocardial infarction and stroke) and serious gastrointestinal events (such as bleeding, ulceration, and perforation). Regulatory documents state that the risk for these serious events may increase with the duration of use and higher doses.

Population-Specific Safety Constraints

Safety constraints exist for specific patient groups, defined in regulatory information. Older adults are cited as being at greater risk for serious gastrointestinal complications. The medication is contraindicated in the third trimester of pregnancy due to fetal risk, and in patients with established cardiovascular disease (e.g., NYHA Class II-IV congestive heart failure) or following Coronary Artery Bypass Graft (CABG) surgery. Monitoring of blood pressure and hepatic/renal function is a general note included in regulatory context for prolonged treatment.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official Regulatory Information for Diastone

This profile is based strictly on the officially documented manifestations and mandated emergency actions for Diclofenac (Diastone) overdose.


Overdose Scope

Property Official Regulatory Statement
Documented overdose presentations The acute profile includes common gastrointestinal symptoms (nausea, vomiting, epigastric pain) and central nervous system effects (lethargy, dizziness, confusion).
Physiological systems affected Systems affected include the Gastrointestinal tract (bleeding, ulceration), Renal system (acute failure), and the Cardiovascular system (hypertension, hypotension).
Population-specific overdose notes Elderly patients face more serious consequences from GI events. Patients with pre-existing asthma may experience wheezing or trouble breathing.
Emergency-response statements Patients must seek emergency medical attention immediately, or contact a certified Poison Control Center.
When immediate medical help is required Immediate medical help is mandated if severe symptoms appear, such as vomiting blood or black/tarry stools, chest pain, shortness of breath, or signs of stroke.

Overdose Classifications (High-Level)

Classification Aspect Official Regulatory Statement
Severity classification Risks range from mild GI/CNS effects to life-threatening complications (e.g., acute renal failure, GI hemorrhage, seizures, coma).
Overdose-context constraints No specific antidote is known; management is limited to supportive and symptomatic treatment.

Resulting Overdose Structure

Official overdose statements:

  • The official profile documents common manifestations including nausea, vomiting, epigastric pain, and confusion.
  • Life-threatening outcomes such as acute renal failure, severe gastrointestinal bleeding, and seizures are explicitly warned against.
  • Patients must seek emergency medical attention immediately upon suspicion of overdose or if severe symptoms are observed.
  • Management requires symptomatic and supportive treatment, as regulatory documents state that no specific antidote is available.

Connection to the overall overdose profile

Regulatory documents define the Diclofenac overdose profile by documenting a spectrum of clinical manifestations and establishing the potential for severe, life-threatening outcomes. This structure mandates the requirement for patients to seek immediate medical attention upon symptom appearance or confirmed exposure, as treatment relies solely on supportive care.

Therapeutic Uses of Diastone

What Diastone Treats: Main Uses and Benefits

Diastone is commonly used to help manage symptoms related to inflammatory or irritative states, including physical discomfort. It is considered relevant when supportive symptom management is appropriate, helping to address symptom clusters that interfere with daily functioning across several therapeutic domains.

This medication is applied across conditions presenting with systemic or localized discomfort, such as Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis, and acute attacks of Gouty Arthritis. It is also relevant for helping to address acute, episodic pain syndromes like Primary Dysmenorrhea (menstrual cramps) and migraine attacks, and is commonly used to help with pain and swelling from post-traumatic injuries and postoperative recovery.

“Diastone assists with the overall symptom load of pain and stiffness, contributing to improved comfort during periods of heightened symptoms.”

It is applied in clinical settings that involve acute or unstable symptom patterns, supporting the patient by easing distress and may assist with maintaining a sense of stability when symptoms become temporarily overwhelming.


Quick Fact: Support for Pain, Inflammation, and Stiffness

Symptom Axis Common Contexts of Use Therapeutic Benefit
Physical Discomfort Acute injuries, Postoperative pain, Menstrual cramps Offers symptomatic relief, assisting with easing distress
Inflammatory States Osteoarthritis, Rheumatoid Arthritis, Gouty Arthritis Plays a role in managing the symptom load related to swelling
Functional Strain Joint stiffness, Impaired mobility May assist with maintaining a sense of stability

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who can and cannot use Diastone?

The official regulatory profile for Diastone (Diclofenac) establishes strict population eligibility rules, defining who is prohibited from using the medicine and who requires conditional use based on established patient criteria.

Category Official Regulatory Status (Based on Labeling)
Populations for whom use is contraindicated Patients with known hypersensitivity to Diclofenac or other NSAIDs (including aspirin-sensitive asthma); Women in the third trimester of pregnancy (ge 30 weeks); Patients with active GI bleeding or ulceration; Treatment of pain immediately following CABG surgery; Individuals with severe hepatic or renal failure; Patients with established cardiovascular disease (e.g., CHF NYHA Class II-IV) (EU/EMA labeling).
Age-related eligibility rules Adults: General use approved. Geriatric: Caution is advised; the lowest effective dose for the shortest duration is recommended. Pediatric: Safety and effectiveness are not established across all age subgroups.
Eligibility-related restrictions Use requires caution and close monitoring for patients with non-severe hepatic or renal impairment. Use between 20 and 30 weeks of pregnancy must be strictly limited. Individuals with cardiovascular risk factors (e.g., hypertension, smoking) should be treated only after careful consideration.

Resulting Eligibility Structure

Official eligibility statements indicate the medicine is contraindicated in patients with severe organ failure, active GI disease, NSAID hypersensitivity, and during the third trimester of pregnancy. The regulatory profile defines eligibility by establishing non-negotiable contraindications tied to these conditions. For other populations, such as the elderly or those with non-severe organ impairment, the official label mandates conditional use or restriction to the lowest effective dose under strict supervision.

What should I know about interactions with other medicines?

Diastone Interactions with other medicines and products

Diastone (generic: spironolactone) has documented interactions with several drug classes and specific medicinal products, primarily impacting potassium balance and the efficacy of co-administered agents. Due to its potassium-sparing nature, concurrent use with other agents that raise serum potassium levels, such as eplerenone, is generally contraindicated. Combining it with potassium supplements or other potassium-sparing diuretics (like amiloride or triamterene) requires careful monitoring to prevent hyperkalemia (abnormally high blood potassium).


Clinically Significant Interactions

Interacting Product Category Key Interaction/Consequence
Agents Increasing Serum Potassium (e.g., eplerenone, potassium supplements, certain salt substitutes) Greatly increased risk of hyperkalemia (high potassium).
NSAIDs (Nonsteroidal Anti-inflammatory Drugs, e.g., ibuprofen) May reduce the diuretic and antihypertensive effects of Diastone.
ACE Inhibitors and Angiotensin II Receptor Blockers (ARBs) Increased risk of severe hyperkalemia.
Lithium May reduce the renal clearance of lithium, leading to a risk of lithium toxicity.
Digoxin Diastone and its metabolites may interfere with certain laboratory tests used to measure digoxin levels.

Additional caution is advised when Diastone is used alongside Cholestyramine, as there have been reports of hyperkalemic metabolic acidosis. The use of acetylsalicylic acid (ASA) may also reduce the effectiveness of Diastone. Any medication, supplement, or herbal product should be discussed with a healthcare professional before co-administration to assess interaction risks.

Mechanism of Action

Enzyme Inhibition and Inflammatory Mediator Suppression

Diclofenac’s core mechanism involves non-selective inhibition of Cyclooxygenase enzymes (COX-1 and COX-2), which are crucial for the synthesis of prostaglandins from arachidonic acid . By suppressing the production of these lipid mediators, the mechanism results in a reduction of prostaglandin-mediated vasodilation and edema at the tissue level, which limits the impact of excessive mediator activity.


Direct Neuronal Pain Signal Blockade

Diclofenac possesses a distinct secondary mechanism where it interacts with and blocks voltage-dependent sodium channels located on peripheral sensory neurons. This molecular action interferes with the rapid electrical conduction necessary for propagating the signal (nociception) along the nerve fiber. This effect contributes to modulating overactive neuronal signaling, resulting in a direct attenuation of nociception.


Modulation of Skeletal Muscle Tone (Diastone Flex)

The combination product, Diastone Flex, includes an ingredient that acts as an antagonist at muscarinic acetylcholine receptors (M-AChRs), primarily in the central nervous system. This targets and modulates the polysynaptic reflex arc in the spinal cord, reducing the efferent signaling that maintains high skeletal muscle contracture. This mechanism promotes a reduction in efferent motor neuron signaling, resulting in a decrease in muscle fiber contracture.

Dosage and Administration Information

How to Use Diastone

The usage of Diastone (Diclofenac) follows standardized administration protocols. The fundamental principle across all formulations is the requirement to use the lowest effective dose for the shortest duration possible, consistent with treatment requirements.


Administration Routes and Dosage Principles

Diastone is approved for systemic use via the oral route (tablets, capsules, and powder for solution) and for localized treatment via the topical route (gels and solutions). Parenteral administration, including intravenous (IV) bolus or infusion and intramuscular (IM) injection, is utilized strictly for short-term management of acute pain.

Dosing is specific to the formulation and indication. For chronic conditions, such as Osteoarthritis, the total daily oral dose typically ranges from 100 mg to 150 mg in divided doses, or as a single 100 mg extended-release tablet once daily. For acute events like migraine, a single dose of 50 mg as an oral powder may be used. The labeled maximum daily dose must not be exceeded for any indication.


Procedural and Contextual Instructions

The method and timing of intake vary by formulation:

  • Oral Solids: Delayed-release or extended-release tablets must be swallowed whole and should not be crushed or chewed. Delayed-release tablets are typically taken preferably before meals.
  • Oral Powder: This formulation must be mixed with a small amount of water only and is typically consumed on an empty stomach to aid absorption.
  • Parenteral: Intravenous use requires that the patient be well hydrated beforehand. The administration of the IV bolus is carried out over a period of at least 15 seconds, and IM use is generally limited to two days.

For older adults, clinical practice involves initiating treatment at the lowest effective dosage within the approved range.

Recent Clinical Evidence

Diastone: Recent Clinical Evidence

The research involving Diastone has primarily used randomized controlled trials (RCTs) and systematic reviews, which are core components of the evidence used to understand how symptoms change over time when compared against an inactive substance or a comparator. This section outlines the types of research and the specific outcomes that were measured for the key conditions Diastone was studied for.


Evidence for Management of Chronic Joint Conditions

Studies focused on chronic inflammatory joint diseases, including Osteoarthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis. Large RCTs explored outcomes related to physical discomfort, such as pain intensity, joint stiffness, and daily functioning or activity level. Findings describe patterns observed in the studies related to these outcomes, though results were mixed when comparing the performance of different topical versus oral formulations.


Evidence for Acute and Episodic Pain Syndromes

For conditions associated with temporary or short-term pain, such as postoperative pain, Primary Dysmenorrhea, and acute migraine attacks, the research involved short-term trials. These studies primarily examined patient-reported outcomes describing perceived discomfort and the need for supplemental analgesic medication. Research provides insight into short-term measured outcomes, but the evidence for these acute uses is limited and often focuses solely on the immediate symptom phase.


Long-Term Studies and Follow-up Duration

Most pivotal RCTs were designed to observe responses over defined intervals, typically up to several months. This means that these studies describe patterns of what has been observed so far in the short- to mid-term, but the follow-up durations were limited when considering chronic conditions. The available research is limited for long-term outcomes and sustained functional status over many years.


Research in Specific Patient Groups and Areas of Uncertainty

Research included adults, and some studies specifically focused on older adults in the context of topical preparations. However, data for certain groups, such as children, remain insufficient within the core research foundation. Furthermore, evidence quality varies across studies, and comparative evidence is lacking in some contexts when examining all available treatment options for every single indication.

Frequently Asked Questions (FAQ)

Common questions about Diastone (FAQ)

Q: Is Diastone meant to be taken long-term?

A: Regulatory documents advise using the lowest effective dosage for the shortest duration possible that is consistent with treatment goals. Regulatory documents indicate that the potential for certain serious adverse events may increase when the medication is used for longer periods.

Q: How quickly should I expect to see an effect from Diastone?

A: The time it takes for Diastone to be absorbed in the body, which is called the onset of absorption, can be delayed by a few hours if the oral form is taken with food. While the body starts processing the drug relatively quickly, the time it takes to experience the full symptom relief can vary for each person and condition.

Q: Is it normal to feel a bit tired when starting Diastone?

A: Official reports of adverse experiences sometimes include central nervous system effects such as drowsiness, a lack of strength or energy known as asthenia, and a general feeling of being unwell, or malaise. These are reported events, but are not necessarily categorized as common.

Q: Can Diastone be taken with a multivitamin?

A: Official product information advises patients to always discuss all medications, vitamins, and herbal products with a healthcare professional before combining them with Diastone. Regulatory labeling advises caution with all concurrent products, as interactions or effects on the medication’s activity are possible with various supplements.

Q: What happens if I miss a dose of Diastone?

A: General patient counseling information describes a typical approach when a dose is missed: to take it when remembered unless it is almost time for the next scheduled intake. To avoid taking more than intended, the information indicates the missed dose is often skipped in favor of returning to the standard schedule.

Q: Can Diastone cause changes in mood or sleep?

A: Regulatory documents list a variety of occasionally reported adverse reactions that involve the nervous system. these include sleep issues like insomnia and dream abnormalities, as well as changes in mood such as depression and anxiety.

Q: How long does the effect of Diastone last after taking it?

A: Pharmacological information states that the drug is eliminated from the body relatively quickly, with the terminal half-life of the unchanged active ingredient being approximately 2 hours. However, the length of time that symptom relief is experienced can be different for each patient and the specific form of the drug being used.

Q: Is Diastone known to cause weight gain or loss?

A: Official regulatory documents list weight changes (both gain and loss) as a reported adverse experience related to the body's metabolic and nutritional system. Additionally, the label notes that the medication may cause fluid retention, which is sometimes reported as swelling or edema.

Q: What is the risk of dependence or addiction with Diastone?

A: According to regulatory classification, Diclofenac, the active ingredient in Diastone, is not classified as a controlled substance. It has no known risk of physical dependence or addiction (abuse potential) as listed in official drug information.

Q: Does alcohol interact negatively with Diastone?

A: Official warnings describe a concern with the concurrent use of alcohol. Taking alcohol while using Diastone can significantly increase the risk of serious gastrointestinal side effects, including the potential for stomach bleeding and ulceration.

Q: Does Diastone need to be taken at a specific time of day?

A: The official product label does not mandate a specific time of day, such as morning or evening. However, some oral forms must be taken at fixed intervals and often require specific instructions, such as taking them before or on an empty stomach, to ensure proper absorption.

Q: If I stop taking Diastone, what happens?

A: Discontinuation of the medication has been described in regulatory context as typically being followed by a return to the pre-treatment state. Official documents note that in patients who developed certain kidney issues related to the drug, discontinuation is followed by recovery to the pretreatment state.

Q: Is Diastone safe to use while breastfeeding (informational)?

A: Official information confirms that the active ingredient, Diclofenac, passes into breast milk in small amounts. While the active ingredient is generally detected in breast milk in small amounts, official label information indicates that caution is necessary, particularly when nursing a newborn or preterm infant.

Q: What happens if I accidentally take two doses of Diastone?

A: Regulatory documents indicate that if accidental ingestion of excess medication (overdose) is suspected, contacting a poison control center or seeking emergency medical attention is the required response. Taking more than the maximum daily dose can lead to serious toxic effects.

Q: Does Diastone have any known interactions with birth control pills?

A: The core regulatory documents for the single-ingredient product do not consistently list a specific drug-to-drug interaction with oral contraceptive pills. However, severe side effects like diarrhea or vomiting caused by Diastone may reduce the effectiveness of oral contraceptives.

Q: Are there any restrictions on driving or operating machinery while using Diastone?

A: Since side effects such as dizziness, vertigo, and visual disturbances can occur, official documents describe the need to avoid driving or operating heavy machinery if certain side effects are experienced.

How should Diastone be stored and disposed of?

Storage and Disposal Requirements

The storage of Diastone must adhere strictly to the conditions specified in official regulatory labeling. The medication must be kept at controlled room temperature, specifically between 20 C and 25 C (68 F to 77 F), with excursions permitted up to 30 C.

Storage Conditions and Handling

The product must be protected from light and moisture and should not be frozen. To maintain integrity, Diastone must remain in its original container and be kept tightly closed.

Mandatory regulatory labeling requires that the medicine be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Diastone must be disposed of according to official regulatory protocols, such as using a drug take-back program. The product must not be flushed down a sink or toilet. If household disposal is necessary, the medicine must be mixed with an unappealing substance, sealed in a bag, and then placed in the trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Diastone found in:

A-Z Index: